Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular Type 2 diabetes drug Ozempic.